125
Participants
Start Date
June 2, 2021
Primary Completion Date
April 25, 2022
Study Completion Date
May 19, 2022
AK111
AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
Placebo
Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
The first affiliated hospital of Bengbu medical college, Bengbu
Peking university people's hospital, Beijing
Peking University Shougang hospital, Beijing
Peking University Third Hospital, Beijing
Xuanwu hospital capital medical university, Beijing
Guangdong provincial people's hospital, Guangzhou
Nanfang Hospital, Guangzhou
The first affiliated hospital of Zhengzhou University, Zhengzhou
Jiangsu Province Hospital, Nanjing
Nanjing Drum Tower hospital, Nanjing
Zhongda Hospital Southeast University, Nanjing
The First Affiliated Hospital of Nanchang University, Nanchang
The first Bethune hospital of Jilin university, Changchun
Second hospital of Shanxi Medical university, Taiyuan
The seventh affiliated hospital, Sun Yat-sen university, Shenzhen
Lead Sponsor
Akeso
INDUSTRY